Education
About Us
Working with TipRanks
Follow Us
Eton Pharmaceuticals Inc (ETON)
NASDAQ:ETON
Total Valuation
Eton Pharmaceuticals has a market cap or net worth of $468.23M. The enterprise value is $578.14M.
Market Cap$468.23M
Enterprise Value$578.14M
Share Statistics
Eton Pharmaceuticals has 26,817,535 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding26,817,535
Owned by Insiders25.28%
Owned by Institutions1.30%
Financial Efficiency
Eton Pharmaceuticals’s return on equity (ROE) is -0.16 and return on invested capital (ROIC) is -4.64%.
Return on Equity (ROE)-0.16
Return on Assets (ROA)-0.05
Return on Invested Capital (ROIC)-4.64%
Return on Capital Employed (ROCE)-0.05
Revenue Per Employee1.26M
Profits Per Employee-123.32K
Employee Count31
Asset Turnover0.51
Inventory Turnover1.02
Valuation Ratios
The current PE Ratio of Eton Pharmaceuticals is ―. Eton Pharmaceuticals’s PEG ratio is -0.29.
PE Ratio―
PS Ratio8.84
PB Ratio14.12
Price to Fair Value14.12
Price to FCF365.77
Price to Operating Cash Flow21.90
PEG Ratio-0.29
Income Statement
In the last 12 months, Eton Pharmaceuticals had revenue of 39.01M and earned -3.82M in profits. Earnings per share was -0.15.
Revenue39.01M
Gross Profit23.41M
Operating Income-2.60M
Pretax Income-3.81M
Net Income-3.82M
EBITDA-1.45M
Earnings Per Share (EPS)-0.15
Cash Flow
In the last 12 months, operating cash flow was 21.31M and capital expenditures -8.42M, giving a free cash flow of 12.89M billion.
Operating Cash Flow21.31M
Free Cash Flow12.89M
Free Cash Flow per Share0.48
Dividends & Yields
Eton Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.16
52-Week Price Change61.38%
50-Day Moving Average18.79
200-Day Moving Average16.44
Relative Strength Index (RSI)38.50
Average Volume (3m)294.15K
Important Dates
Eton Pharmaceuticals upcoming earnings date is Mar 12, 2026, TBA (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateMar 12, 2026
Ex-Dividend Date―
Financial Position
Eton Pharmaceuticals as a current ratio of 2.06, with Debt / Equity ratio of 14.08%
Current Ratio2.06
Quick Ratio1.29
Debt to Market Cap0.09
Net Debt to EBITDA-10.33
Interest Coverage Ratio-1.30
Taxes
In the past 12 months, Eton Pharmaceuticals has paid 15.00K in taxes.
Income Tax15.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Eton Pharmaceuticals EV to EBITDA ratio is -248.04, with an EV/FCF ratio of 381.66.
EV to Sales9.23
EV to EBITDA-248.04
EV to Free Cash Flow381.66
EV to Operating Cash Flow371.42
Balance Sheet
Eton Pharmaceuticals has $37.12M in cash and marketable securities with $3.26M in debt, giving a net cash position of $33.87M billion.
Cash & Marketable Securities$37.12M
Total Debt$3.26M
Net Cash$33.87M
Net Cash Per Share$1.26
Tangible Book Value Per Share-$0.40
Margins
Gross margin is 51.36%, with operating margin of -6.66%, and net profit margin of -9.80%.
Gross Margin51.36%
Operating Margin-6.66%
Pretax Margin-9.76%
Net Profit Margin-9.80%
EBITDA Margin-3.72%
EBIT Margin-6.66%
Analyst Forecast
The average price target for Eton Pharmaceuticals is $35.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$35.00
Price Target Upside107.35% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast102.77%
EPS Growth Forecast-17.00%